Dr. Prasanna Jagannathan is an Infectious Diseases specialist with 7 years of experience in translational immunology research focused on pathogen-specific cellular immune responses. His current research program is to further our understanding of the mechanisms of clinical immunity to malaria through field-based studies, and to better understand the immunologic consequences of malaria control interventions.

Given the profound global impact of the COVID-19 pandemic, Dr. Jagannathan's group is also testing novel immune modulating therapeutics for the treatment of SARS-CoV-2 infected patients with mild infection (NCT 04331899). In this study 120 SARS-CoV-2 infected patients (both symptomatic and asymptomatic) are being randomized to receive Lambda vs. placebo to test the hypothesis that SARS-CoV-2-infected individuals given Lambda at the time of diagnosis have a shortened duration of viral shedding in comparison to patients given placebo. Dr. Jagannathan serves as as the co-PI of this study along with Dr. Upi Singh at Stanford.